We're pleased to announce our 2026 guideline update to induction treatment for cryptococcal meningitis! sahivsoc.org/Files/SAHCS%... @neleshg.bsky.social @tomboylesid.bsky.social #HIV #CryptococcalMeningitis

I am honored to have hosted a delegation from Dutch Ministry of Foreign Affairs led by @pdhof.bsky.social.

We had productive discussions focused on our long-standing R&D partnership for #NTDs like visceral #leishmaniasis & our work developing innovative treatments for #cryptococcalmeningitis.

#CryptococcalMeningitis is the 2nd-leading cause of #HIV-related deaths. We're excited to announce that a new sustained-release formulation of flucytosine, used to treat cryptococcal meningitis, has entered Phase II clinical trials in #Malawi & #Tanzania.

👉 Read more: bit.ly/3G5Yfis

A single-dose liposomal amphotericin protocol plus fluconazole and flucytosine for #CryptococcalMeningitis in patients with #HIV demonstrated similar mortality and recurrence rates but fewer severe adverse events and shorter hospitalizations. ja.ma/45rkXLW

New case report: APS + #CryptococcalMeningitis after immunosuppressive treatment. Highlights how headache/neuro symptoms can overlap with clot-related events—so infection may need checking in immunosuppressed patients. Read: pmc.ncbi.nlm.nih.gov/articles/PMC... #APS #RareDisease #MedResearch

New guidance on #cryptococcalmeningitis induction therapy is here Join our webinar to see how the AMBITION-cm trial has changed clinical practice
Live: 19 March | 17h30 SAST → us02web.zoom.us/webinar/regi... Pre-recorded: 24 March | 13h00 SAST → us02web.zoom.us/webinar/regi...
@neleshg.bsky.social